Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Roundhill Magnificent Seven ETF — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Roundhill Magnificent Seven ETF trades at $72.17 (market cap $5.85B). The key difference: Kymera Therapeutics Inc. Common Stock is the larger of the two by market cap, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, Kymera Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Roundhill Magnificent Seven ETF for 35 Days on average.
| KYMR | MAGS | |
|---|---|---|
Market Cap | $8.88B | $5.85B |
Volume | 1,028,790 | 4,954,846 |
Sector | Health | Sector/Thematic |
52-Week High | $127.31 | $74.30 |
52-Week Low | $55.80 | $55.39 |
Typical Hold Time | 0 Days | 35 Days |
Enterprise Value | $8.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MAGS (Roundhill Magnificent Seven ETF) trades at $74.3, up 0.43% today, with a bullish technical signal from moving averages but a neutral stance from oscillators. The ETF provides equal-weighted exposure to seven mega-cap tech leaders, though it has underperformed the S&P 500 in 2026 with only a 2% year-to-date gain. Recent news highlights AI-driven growth potential but also notes fracturing in the 'Magnificent Seven' trade theme.
The outlook for MAGS hinges on AI innovation sustaining mega-cap earnings, but risks include concentration liability and market rotation. Upside is tied to tech leadership in AI supercycle, while underperformance versus broader indexes signals investor caution. Key support sits at $73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
